Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients

References

• Gomez-Pinillos A, Ferrari AC. mTOR signaling pathway and mTOR inhibitors in cancer therapy. Hematol Oncol Clin North Am. 2012;26(3):483–505, vii. doi:10.1016/j.hoc.2012.02.01422520976
   PubMed Web of Science ®Google Scholar
• Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol. 2011;9(2):98–109. doi:10.1038/nrclinonc.2011.19222182972
   PubMed Web of Science ®Google Scholar
• Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol. 2011;23(6):578–586. doi:10.1097/CCO.0b013e32834b892d21892085
   PubMed Web of Science ®Google Scholar
• Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol. 2014;9(3):183–193. doi:10.1007/s11523-013-0303-824243495
   PubMed Web of Science ®Google Scholar
• Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45. doi:10.1186/1756-8722-2-4519860903
   PubMed Web of Science ®Google Scholar
• Meng LH, Zheng XF. Toward rapamycin analog (rapalog)-based precision cancer therapy. Acta Pharmacol Sin. 2015;36(10):1163–1169. doi:10.1038/aps.2015.6826299952
   PubMed Web of Science ®Google Scholar
• Martins F, de Oliveira MA, Wang Q, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol. 2013;49(4):293–298. doi:10.1016/j.oraloncology.2012.11.00823312237
   PubMed Web of Science ®Google Scholar
• Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116(1):210–215. doi:10.1002/cncr.2469619862817
   PubMed Web of Science ®Google Scholar
• Boers-Doets CB, Raber-Durlacher JE, Treister NS, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol. 2013;9(12):1883–1892. doi:10.2217/fon.13.14124295418
   PubMed Web of Science ®Google Scholar
• Peterson DE, O’Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897–1907. doi:10.1002/cam4.2016.5.issue-827334013
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Rapamycin VC. (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28(10):727–732. doi:10.7164/antibiotics.28.7271102509
   PubMed Web of Science ®Google Scholar
• Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR mediated anti-cancer drug discovery. Drug Discov Today Ther Strateg. 2009;6(2):47–55. doi:10.1016/j.ddstr.2009.12.00120622997
   PubMedGoogle Scholar
• Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008;44(1):84–91. doi:10.1016/j.ejca.2007.10.00318039566
   PubMed Web of Science ®Google Scholar
• Boers-Sonderen MJ, de Geus-Oei LF, Desar IM, et al. Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Target Oncol. 2014;9(4):339–347. doi:10.1007/s11523-014-0309-x24577626
   PubMed Web of Science ®Google Scholar
• Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma. Semin Oncol. 2009;36(Suppl 3):S26–S36. doi:10.1053/j.seminoncol.2009.10.01319963097
   PubMedGoogle Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811. doi:10.1056/NEJMoa100167121047224
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–456. doi:10.1016/S0140-6736(08)61039-918653228
   PubMed Web of Science ®Google Scholar
• Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients’ experience of oral mucositis. Oncol Nurs Forum. 2002;29(7):1051–1057. doi:10.1188/02.ONF.1051-105712183754
   PubMedGoogle Scholar
• Lo Muzio L, Arena C, Troiano G, Villa A. Oral stomatitis and mTOR inhibitors: a review of current evidence in 20,915 patients. Oral Dis. 2018;24(1–2):144–171. doi:10.1111/odi.1279529480626
   PubMed Web of Science ®Google Scholar
• Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol. 2014;25(4):808–815. doi:10.1093/annonc/mdu00924615500
   PubMed Web of Science ®Google Scholar
• Boers-Doets C, Lalla RV. The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Supp Care Cancer. 2013;21(Suppl):1.
   PubMedGoogle Scholar
• Ji YD, Aboalela A, Villa A. Everolimus-associated stomatitis in a patient who had renal transplant. BMJ Case Rep. 2016;2016.
   PubMedGoogle Scholar
• Kalogirou EM, Tosios KI, Piperi EP, Sklavounou A. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(1):e13–e19. doi:10.1016/j.oooo.2014.08.02325442249
   PubMed Web of Science ®Google Scholar
• Ferte C, Soria JC, Penel N. Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One. 2011;6(3):e16633. doi:10.1371/journal.pone.001663321415927
   PubMed Web of Science ®Google Scholar
• Nicolatou-Galitis O, Nikolaidi A, Athanassiadis I, Papadopoulou E, Sonis S. Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(2):e110–e116. doi:10.1016/j.oooo.2013.02.02223643584
   PubMed Web of Science ®Google Scholar
• Rugo HS, Seneviratne L, Beck JT, et al.Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;(18):654–662. doi:10.1016/S1470-2045(17)30109-228314691
   PubMedGoogle Scholar
• Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438–2446. doi:10.1002/cncr.v115:1119306412
   PubMed Web of Science ®Google Scholar
• Andre F, O’Regan R, Ozguroglu M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(6):580–591. doi:10.1016/S1470-2045(14)70138-X24742739
   PubMed Web of Science ®Google Scholar
• Angelousi A, Kamp K, Kaltsatou M, O’Toole D, Kaltsas G, de Herder W. Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatments. Neuroendocrinology. 2017;105(4):394–402. doi:10.1159/00045603528122378
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388. doi:10.1016/S1470-2045(15)00515-X26794930
   PubMed Web of Science ®Google Scholar
• Bajetta E, Catena L, Fazio N, et al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014;120(16):2457–2463. doi:10.1002/cncr.2872624752410
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529. doi:10.1056/NEJMoa110965322149876
   PubMed Web of Science ®Google Scholar
• Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–2637. doi:10.1200/JCO.2008.18.839119380449
   PubMed Web of Science ®Google Scholar
• Bergmann L, Kube U, Doehn C, et al. Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study. BMC Cancer. 2015;15:303. doi:10.1186/s12885-015-1309-725925846
   PubMed Web of Science ®Google Scholar
• Besse B, Leighl N, Bennouna J, et al. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Ann Oncol. 2014;25(2):409–415. doi:10.1093/annonc/mdt53624368400
   PubMed Web of Science ®Google Scholar
• Campone M, Levy V, Bourbouloux E, et al. Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer. 2009;100(2):315–321. doi:10.1038/sj.bjc.660485119127256
   PubMed Web of Science ®Google Scholar
• Castellano D, Bajetta E, Panneerselvam A, et al. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2013;18(1):46–53. doi:10.1634/theoncologist.2012-026323263288
   PubMed Web of Science ®Google Scholar
• Chan JA, Blaszkowsky L, Stuart K, et al. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer. 2013;119(17):3212–3218. doi:10.1002/cncr.2814223733618
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. doi:10.1056/NEJMoa151001626406150
   PubMed Web of Science ®Google Scholar
• Chow H, Ghosh PM, deVere White R, et al. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016;122(12):1897–1904. doi:10.1002/cncr.2992727019001
   PubMed Web of Science ®Google Scholar
• Chung V, Frankel P, Lim D, et al. Phase Ib trial of mFOLFOX6 and everolimus (NSC-733504) in patients with metastatic gastroesophageal adenocarcinoma. Oncology. 2016;90(6):307–312. doi:10.1159/00044529727093189
   PubMed Web of Science ®Google Scholar
• Ciruelos E, Vidal M, Martinez de Duenas E, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain. Clin Transl Oncol. 2017.
   Web of Science ®Google Scholar
• Ciunci CA, Perini RF, Avadhani AN, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 2014;120(1):77–85. doi:10.1002/cncr.2829424108668
   PubMed Web of Science ®Google Scholar
• Colon-Otero G, Weroha SJ, Foster NR, et al. Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers. Gynecol Oncol. 2017;146(1):64–68. doi:10.1016/j.ygyno.2017.04.02028461031
   PubMed Web of Science ®Google Scholar
• Courtney KD, Manola JB, Elfiky AA, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(2):113–123. doi:10.1016/j.clgc.2014.08.00725450031
   PubMed Web of Science ®Google Scholar
• Deenen MJ, Klumpen HJ, Richel DJ, et al. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. Invest New Drugs. 2012;30(4):1557–1565. doi:10.1007/s10637-011-9723-421809026
   PubMed Web of Science ®Google Scholar
• Doi T, Muro K, Boku N, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28(11):1904–1910. doi:10.1200/JCO.2009.26.292320231677
   PubMed Web of Science ®Google Scholar
• El-Madani M, Colomban O, Tod M, et al. EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib. Future Oncol. 2017;13(8):679–693. doi:10.2217/fon-2016-035728076966
   PubMed Web of Science ®Google Scholar
• Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–235. doi:10.1016/j.ejca.2016.08.00427680407
   PubMed Web of Science ®Google Scholar
• Fazio N, Granberg D, Grossman A, et al. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2013;143(4):955–962. doi:10.1378/chest.12-110823187897
   PubMed Web of Science ®Google Scholar
• Ferolla P, Brizzi MP, Meyer T, et al. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2017;18(12):1652–1664. doi:10.1016/S1470-2045(17)30681-229074099
   PubMed Web of Science ®Google Scholar
• Finn RS, Poon RT, Yau T, et al. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol. 2013;59(6):1271–1277. doi:10.1016/j.jhep.2013.07.02923928403
   PubMed Web of Science ®Google Scholar
• Fury MG, Sherman E, Haque S, et al. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;69(3):591–598. doi:10.1007/s00280-011-1734-521913034
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1408–1414. doi:10.1200/JCO.2009.24.099420142598
   PubMed Web of Science ®Google Scholar
• Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015;46(3):783–794. doi:10.1183/09031936.0021071426113676
   PubMed Web of Science ®Google Scholar
• Gong C, Zhao Y, Wang B, et al. Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study. Oncotarget. 2017;8(35):59810–59822. doi:10.18632/oncotarget.v8i3528938684
   PubMedGoogle Scholar
• Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107. doi:10.1016/S1470-2045(14)71136-225498219
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28(13):2131–2136. doi:10.1200/JCO.2009.26.315220368560
   PubMed Web of Science ®Google Scholar
• Hatano T, Chikaraishi K, Inaba H, Endo K, Egawa S. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan. Int J Urol. 2016;23(10):833–838. doi:10.1111/iju.2016.23.issue-1027480662
   PubMed Web of Science ®Google Scholar
• Hatano T, Atsuta M, Inaba H, Endo K, Egawa S. Effect of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: an evaluation based on tumor density. Int J Clin Oncol. 2017.
   Web of Science ®Google Scholar
• Hurvitz SA, Dalenc F, Campone M, et al. A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy. Breast Cancer Res Treat. 2013;141(3):437–446. doi:10.1007/s10549-013-2689-524101324
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Mariani G, Ciruelos EM, et al. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). Ann Oncol. 2016;27(9):1719–1725. doi:10.1093/annonc/mdw24927358383
   PubMed Web of Science ®Google Scholar
• Jovanovic B, Mayer IA, Mayer EL, et al. A randomized Phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III Triple-Negative Breast Cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res. 2017;23(15):4035–4045. doi:10.1158/1078-0432.CCR-16-305528270498
   PubMed Web of Science ®Google Scholar
• Jozwiak S, Kotulska K, Berkowitz N, Brechenmacher T, Franz DN. Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr. 2016;172:151–155 e151. doi:10.1016/j.jpeds.2016.01.02726858193
   PubMed Web of Science ®Google Scholar
• Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment. Jpn J Clin Oncol. 2014;44(5):479–485. doi:10.1093/jjco/hyu01824688083
   PubMed Web of Science ®Google Scholar
• Kim DW, Oh DY, Shin SH, et al. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer. 2014;14:795. doi:10.1186/1471-2407-14-79525362970
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee W, Kim TN, Nam JK, Kim TH, Lee KS. Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: A multicentre study in Korea. Can Urol Assoc J. 2018;12(1):E15–E20. doi:10.5489/cuaj.464429173270
   PubMed Web of Science ®Google Scholar
• Koutsoukos K, Bamias A, Tzannis K, et al. Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib. Onco Targets Ther. 2017;10:4885–4893. doi:10.2147/OTT29062235
   PubMed Web of Science ®Google Scholar
• Kulke MH, Ruszniewski P, Van Cutsem E, et al. A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Ann Oncol. 2017;28(6):1309–1315. doi:10.1093/annonc/mdx07828327907
   PubMed Web of Science ®Google Scholar
• Kumano M, Miyake H, Harada K, Fujisawa M. Sequential use of mammalian target of rapamycin inhibitors in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitors. Med Oncol. 2013;30(4):745. doi:10.1007/s12032-013-0745-y24122255
   PubMed Web of Science ®Google Scholar
• Moscetti L, Vici P, Gamucci T, et al. Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: a multicenter Italian experience. Breast. 2016;29:96–101. doi:10.1016/j.breast.2016.07.00527476084
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Alyasova A, Ye D, et al. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). Ann Oncol. 2016;27(3):441–448. doi:10.1093/annonc/mdv61226681676
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. doi:10.1200/JCO.2013.54.691125049330
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–1482. doi:10.1016/S1470-2045(15)00290-926482279
   PubMed Web of Science ®Google Scholar
• Oh DY, Kim TW, Park YS, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer. 2012;118(24):6162–6170. doi:10.1002/cncr.2767522736481
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Ajani JA, Bai YX, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935–3943. doi:10.1200/JCO.2012.48.355224043745
   PubMed Web of Science ®Google Scholar
• Ohyama K, Matsumoto Y, Amamizu H, et al. Association of coronary perivascular adipose tissue inflammation and drug-eluting stent-induced coronary hyperconstricting responses in pigs: (18)F-fluorodeoxyglucose positron emission tomography imaging study. Arterioscler Thromb Vasc Biol. 2017;37(9):1757–1764. doi:10.1161/ATVBAHA.117.30984328751570
   PubMed Web of Science ®Google Scholar
• Panzuto F, Rinzivillo M, Fazio N, et al. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014;19(9):966–974. doi:10.1634/theoncologist.2014-003725117065
   PubMed Web of Science ®Google Scholar
• Park K, Lee JL, Ahn JH, et al. Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor. Cancer Res Treat. 2014;46(4):339–347. doi:10.4143/crt.2013.15425036572
   PubMed Web of Science ®Google Scholar
• Pavel M, Unger N, Borbath I, et al. Safety and QOL in patients with advanced NET in a Phase 3b expanded access study of everolimus. Target Oncol. 2016;11(5):667–675. doi:10.1007/s11523-016-0440-y27193465
   PubMed Web of Science ®Google Scholar
• Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871–879. doi:10.1158/1078-0432.CCR-10-262121177764
   PubMed Web of Science ®Google Scholar
• Safra T, Kaufman B, Kadouri L, et al. Everolimus plus letrozole for treatment of patients with HR(+), HER2(-) advanced breast cancer progressing on endocrine therapy: an open-label, Phase II trial. Clin Breast Cancer. 2017.
   PubMed Web of Science ®Google Scholar
• Salazar R, Garcia-Carbonero R, Libutti SK, et al. Phase II study of BEZ235 versus Everolimus in patients with mammalian target of rapamycin inhibitor-naive advanced pancreatic neuroendocrine tumors. Oncologist. 2017.
   Web of Science ®Google Scholar
• Sarkaria JN, Galanis E, Wu W, et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(2):468–475. doi:10.1016/j.ijrobp.2010.05.06420864273
   PubMed Web of Science ®Google Scholar
• Strickler JH, Starodub AN, Jia J, et al. Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(2):251–258. doi:10.1007/s00280-012-1911-122744359
   PubMed Web of Science ®Google Scholar
• Sun JM, Kim JR, Do IG, et al. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer. 2013;109(6):1482–1487. doi:10.1038/bjc.2013.46723963141
   PubMed Web of Science ®Google Scholar
• Takahashi K, Uchida K, Yoshimura N, et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results. Transplant Res. 2013;2(1):14. doi:10.1186/2047-1440-2-1423866828
   PubMedGoogle Scholar
• Tobinai K, Ogura M, Maruyama D, et al. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol. 2010;92(4):563–570. doi:10.1007/s12185-010-0707-520972652
   PubMed Web of Science ®Google Scholar
• Vlahovic G, Meadows KL, Uronis HE, et al. A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(1):95–102. doi:10.1007/s00280-012-1889-822638798
   PubMed Web of Science ®Google Scholar
• Wang M, Popplewell LL, Collins RH Jr., et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165(4):510–518. doi:10.1111/bjh.2014.165.issue-424579926
   PubMed Web of Science ®Google Scholar
• Werner D, Atmaca A, Pauligk C, Pustowka A, Jager E, Al-Batran SE. Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma. Cancer Med. 2013;2(3):325–333. doi:10.1002/cam4.7723930209
   PubMed Web of Science ®Google Scholar
• Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27(2):193–198. doi:10.1200/JCO.2008.18.951419047305
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–4318. doi:10.1200/JCO.2008.16.785818779618
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–523. doi:10.1056/NEJMoa100929021306238
   PubMed Web of Science ®Google Scholar
• Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006;12(17):5165–5173. doi:10.1158/1078-0432.CCR-06-076416951235
   PubMed Web of Science ®Google Scholar